3- Phenyl-2-hydroxy-477-pyrido

Stmctures of 3-hydroxy-3-phenyl-3,4-dihydro-l/7- <2006JST(792)36>, l-hydroxy-l-methyl-3-phenyl-17/-pyrido[2,l-c]-... 

Phenyl-2//-pyrido 2,3-<7 [l,3]oxazine-2,4(l//)-dione (64) with diethyl malo-nate gave ethyl 4-hydroxy-2-oxo-l-phenyl-l,2-dihydro-l,8-naphthyridine-3-carboxylate (65) (reactants, NaH, 150°C 85%) 453,407 the same substrate (64) with ethyl nitroacetate gave 4-hydroxy-3-nitro-l-phenyl-1,8-naphthyr-idin-2(lfl)-one (66) (NaH/MeCONMe2, 100°C 77%).1191... 

Acetyl-4-hydroxy-3-methyl-1-phenyl- H- (pyrido 2,3-c]-pyrazol) 70% ... 

Theoretical calculations (B3LYP/6-31G ) were reported for geometries (bond lengths and bond angles) and chemical shifts of 3-methyl- and 3-phenyl-4-hydroxy-2-oxo-2/7-pyrido[2,l-f>][l, 3]oxazinium inner salts (00JCS(P2)2096). 

Methyl- and 3-phenyl-4-hydroxy-2-oxo-2//-pyrido[2,1 -Z)]oxazinium inner salts were prepared in the reaction of 2-pyridone and 2-substituted malonyl chloride, prepared in situ from 2-substituted malonic acid with PCI5 in CH2CI2 (00JCS(P2)2096). 

The solid state structures of anhydro-(3-methy - and 3-phenyl-2-hydroxy-4-oxo-47/-pyrido[l,2-n]pyridinium)hydroxides, 2-methoxy-3-methyl-47/-and 2-(2-pyridylamino)-47/-pyrido[l, 2-n]pyrimidin-4-ones were established by X-ray diffraction analysis. The amide type N(5)-C(4)-0 bonds are unusually long (144-149 pm) showing no sign of an amide type conjugation. 

The relative stereostructure of 9-acetyl-7-hydroxy-l,2-dimethyl-7-meth-oxycarbonyl-4-phenyl-6-oxo-l, 4,7,8-tetrahydro-6/7-pyrido[l, 2-u]pyri-midine-3-carboxylate 122 was justified by an X-ray diffraction analysis (97JOC3109). The stereochemistry and solid state structure of racemic trans-6,9-//-l, 6-dimethyl-9 z-ethoxy-9-hydroxy-4-oxo-l,6,7,8,9,9 z-hexahydro-4//-pyrido[l,2- z]pyrimidine-3-carboxylate (123), adopting a cw-fused conformation, were determined by X-ray investigations (97H(45)2175). 

Free radical polymerization of n / yJro-(2-hydroxy-3-[(3-vinylphenyl)-methyl]-l-phenyl-4-oxo-4//-pyrido[l,2-n]pyrimidinium)hydroxide in DMF at 60 °C for 2 days in the presence of 2,2 -azoizobutyronitrile led to a mesoionic polymer (00MI26). 

Hydrazone of 1 -hydrazino-1 -hydroxy-4-phenyl-1,2-dihydro-3//-pyrido [l,2-c]pyrimidin-3-one was patented as cross-linkers for making physiologically compatible and H2O insoluble hydrazine or hydrazono compounds (97JAP(K)97/59303). 

Stereostructures of a co-crystal of (li )-l- 4-[(9aA)-perhydropyrido[l,2- ]pyrazin-2-yl]phenyl -2-phenyl-7-hydroxy-l, 2,3,4-tetrahydroisoquinoline with ERa-LBD301-553/C — S triple mutant <2005JME364> and iV-[2-(4-hydroxyphenyl)ethyl]-a-propyl-3-[(4-hydroxyphenyl)methyl]-l,4-dioxo-l,2,3,4,ll,l la-hexahydro-67/-pyrazino[l,2- ]isoquinoline-3-acetamide with fructose-1,6-biphosphatase <2003JBC51176> were determined by X-ray crystallography. The structure of a complex formed from 3-[( -methylphenyl)amino]-4-[(4-methylphenyl)imino]-4//-pyrido[l,2-tf]pyrazine with sodium bis(trimethylsilyl)amide and (norbornadiene)Mo(CO)4 in THF was characterized by single crystal X-ray diffraction <1995JPR38>. 

Mild acidic hydrolysis of amino nitrile 369 gave m-4,9a-/7-rra r-9-7/-9-benzyloxy-4-phenyl-3,4,9,9a-tetrahydro-17/,67/-pyrido[2,l-d[l,4]oxazin-l-one <1996TL4001>. (2A)-2-Cyano-l-[(lR)-2-hydroxy-l-phenylethyl]piperidin-6-one, on standing for 20 days in ethanol saturated with HC1 gas, afforded (4/ ,9aA)-4-phenylperhydropyrido[l,2-4[l,4]oxazine-l,6-dione, which was sometimes accompanied by the unstable (26 )-l-[(l/ )-2-hydroxy-l-phenylethyl]-... 

Reaction of 3-formyM/7-pyrido[ 1,2- ]pyrimidin-l-ones with hydroxylamine O-sulfonic acid at 5 °C, then 50 °C yielded 3-nitriles <2003T4113>. Treatment of 2-hydroxy-3-(dimethylamono)methyF4//-pyrido[l,2- ]pyrimidin-4-one with Mel, then with KCN gave the 3-cyanomethyl derivative <2004MI215>. A condensation product was obtained from 5-amino-l-ethyl-6-hydroxy-l,3-dihydrobenzimidazol-2-one and 3-lbrmyl-2-hydroxyA//-pyndo[ 1,2- ]pynmidin-l-one <2002W002/38549>. l-(2-Aminopyrimidin-4-yl)-8-phenyl-l,2,3,4-tetrahydro-6//-pyrido[l,2- ]pyrimidin-6-ones were prepared from l-(2-methylthiopyrimidin l-yl)-8-phenyl-l,2,3,4-tetrahydro-6//-pyrido[l,2- ]pyrimidin-6-one by treatment with MCPBA, and then with aralkylamines <2005W005/070932>. 

---